NASDAQ:LOGC (LogicBio Therapeutics)
About LOGC
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases. It is committed to delivering genetic medicine to pediatric patients with rare diseases. Their proprietary technology based on the non-pathogenic adeno-associated viral vector offers superior efficiency and safety compared to all competitors on the market and is uniquely suited for the treatment of children as well as adults.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Profiles by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Financials by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Share Information by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Dividends by EDI/Mergent (USA) and TSX (CDN).
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Earnings and Analyst Ratings by Zacks.
Earnings Events by Wall Street Horizon.
Terms of Use.